InspireMD Receives Regulatory Approval for both CGuard EPS™ and MGuard Prime™ in Ecuador
16 mai 2018 08h12 HE
|
InspireMD, Inc.
Tel Aviv, Israel, May 16, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...
InspireMD Reports 132% Increase in CGuard™ EPS Sales for the First Quarter of 2018
07 mai 2018 16h05 HE
|
InspireMD, Inc.
Tel Aviv, Israel, May 07, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
InspireMD Schedules First Quarter 2018 Earnings Conference Call
01 mai 2018 07h00 HE
|
InspireMD, Inc.
TEL AVIV, ISRAEL , May 01, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...
InspireMD Announces Regulatory Approval and Reimbursement to Commercialize both CGuard EPS™ and MGuard™ Prime Products in Vietnam
30 avr. 2018 07h34 HE
|
InspireMD, Inc.
TEL AVIV, ISRAEL, April 30, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
InspireMDs CGuard Embolic Prevention System to be Featured at ICCA Stroke 2018 in Warsaw, Poland
19 avr. 2018 07h00 HE
|
InspireMD, Inc.
TEL AVIV, ISRAEL, April 19, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
InspireMD Anticipates Fifth Consecutive Quarter of Sequential Double Digit Growth; Projects 132% Increase in CGuard EPS Sales for the First Quarter of 2018; Total Quarterly Company Sales to Exceed $1 Million
03 avr. 2018 10h28 HE
|
InspireMD, Inc.
TEL AVIV, Israel, April 03, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
InspireMD, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock
28 mars 2018 06h30 HE
|
InspireMD, Inc.
Tel Aviv, Israel, March 28, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular...
InspireMD, Inc. Announces Proposed Public Offering of Common Stock
27 mars 2018 16h37 HE
|
InspireMD, Inc.
Tel Aviv, Israel, March 27, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular...
InspireMD Receives Regulatory Approval for both CGuard™ EPS and MGuard Prime™ in Peru
27 mars 2018 07h00 HE
|
InspireMD, Inc.
Tel Aviv, Israel, March 27, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
InspireMD Announces First Patient Treated with CGuard™ EPS in India
05 mars 2018 08h07 HE
|
InspireMD, Inc.
Patient with severe stenosis, calcification and thrombosis successfully treated with CGuard™ EPS TEL AVIV, ISRAEL, March 05, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader...